Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) EBIT: 2020-2023

Historic EBIT for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$33.2 million.

  • Therapeutics' EBIT fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • Therapeutics' EBIT amounted to -$33.2 million in Q4 2023, which was up 2.07% from -$33.9 million recorded in Q3 2023.
  • Over the past 5 years, Therapeutics' EBIT peaked at -$12.5 million during Q2 2020, and registered a low of -$33.9 million during Q3 2023.
  • Over the past 3 years, Therapeutics' median EBIT value was -$21.2 million (recorded in 2022), while the average stood at -$23.5 million.
  • Data for Therapeutics' EBIT shows a maximum YoY crashed of 56.47% (in 2023) over the last 5 years.
  • Over the past 4 years, Therapeutics' EBIT (Quarterly) stood at -$13.1 million in 2020, then plummeted by 37.82% to -$18.0 million in 2021, then slumped by 35.47% to -$24.4 million in 2022, then slumped by 35.96% to -$33.2 million in 2023.
  • Its EBIT stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.